Eli Lilly's advertising for Zepbound highlights a key competitive strategy: timing head-to-head trials against a competitor's drug just before a more effective, higher-dose version is approved. This allows Lilly to legally promote a 'dramatic superiority' message based on now-outdated data, forcing Novo Nordisk into a reactive legal battle.

The ad spending disparity between Eli Lilly ($67.8M/quarter for Zepbound) and Novo Nordisk (not in the top 10) may reflect different corporate cultures. US-based Lilly is native to the aggressive direct-to-consumer (DTC) ad environment. European Novo, from a region where DTC ads are banned, may have a fundamentally different marketing mindset.

The dynamic between Novo Nordisk and Eli Lilly in the obesity market has evolved. Initially, they worked in parallel to legitimize therapeutic treatment for obesity and combat unregulated compounders. With compounding now restricted, their shared enemies are gone, and the rivalry has escalated into direct, aggressive brand-versus-brand competition, exemplified by Novo's lawsuit.

Despite its first-mover advantage, Novo Nordisk lost its lead in the weight-loss drug market by failing to recognize its consumer-driven nature. While it planned a traditional pharma launch, competitor Eli Lilly adopted a direct-to-consumer model, treating the drug like an e-commerce product and capturing the market.

In an aggressive commercial move, Novo Nordisk partnered with telehealth company Hims to distribute its branded obesity drug. This is notable because Hims was recently reprimanded by the FDA for trying to sell a compounded version. Novo is turning a potential adversary into a distribution channel to maximize market reach.

Novo Nordisk's head-to-head trial of its Cagracemma against Lilly's Zepbound was a major strategic error. Instead of demonstrating superiority, the study showed Zepbound was more effective, wiping $26 billion from Novo's market cap. Novo effectively funded a large-scale clinical trial that validated its primary competitor's product.

The obesity drug market is seeing prices cut in half much faster than anticipated, despite being a duopoly. This rapid price degradation is driven by Novo Nordisk, the market laggard, aggressively using price as a weapon to reclaim market share from Eli Lilly, a dynamic typically seen only after multiple new players enter.

Instead of directly competing with Lilly and Novo Nordisk, Boehringer Ingelheim's obesity strategy will focus on "clinical inertia." They see the primary challenge as activating the 90% of the 100 million eligible US patients not yet receiving evidence-based treatment.

After lagging Eli Lilly in the injectable obesity drug market, Novo Nordisk has reversed the dynamic by successfully launching its oral version, Wagovi pill, first. This head start has given Novo a substantial lead in sales and prescriptions in the new oral segment, demonstrating how a shift in drug delivery format can completely reset a competitive landscape.